ARQT Quote, Financials, Valuation and Earnings

CytomX Therapeutics has a net margin of -92.81% compared to Arcutis Biotherapeutics's net margin of 17.16%. Arcutis Biotherapeutics's return on equity of -138.99% beat CytomX Therapeutics's return on equity of --.

Arcutis Biotherapeutics has a consensus price target of $19.13, signalling upside risk potential of 25.25%. On the other hand CytomX Therapeutics has an analysts' consensus of $4.69 which suggests that it could grow by 376.8%. Given that CytomX Therapeutics has higher upside potential than Arcutis Biotherapeutics, analysts believe CytomX Therapeutics is more attractive than Arcutis Biotherapeutics.

Arcutis Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CytomX Therapeutics has a beta of 1.030, suggesting its more volatile than the S&P 500 by 2.991%.

Arcutis Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytomX Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics pays -- of its earnings as a dividend. CytomX Therapeutics pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics quarterly revenues are $44.8M, which are larger than CytomX Therapeutics quarterly revenues of $33.4M. Arcutis Biotherapeutics's net income of -$41.5M is lower than CytomX Therapeutics's net income of $5.7M. Notably, Arcutis Biotherapeutics's price-to-earnings ratio is -- while CytomX Therapeutics's PE ratio is 5.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics is 12.54x versus 0.65x for CytomX Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Kodiak Sciences has a net margin of -92.81% compared to Arcutis Biotherapeutics's net margin of --. Arcutis Biotherapeutics's return on equity of -138.99% beat Kodiak Sciences's return on equity of --.

Arcutis Biotherapeutics has a consensus price target of $19.13, signalling upside risk potential of 25.25%. On the other hand Kodiak Sciences has an analysts' consensus of $6.67 which suggests that it could fall by -27.54%. Given that Arcutis Biotherapeutics has higher upside potential than Kodiak Sciences, analysts believe Arcutis Biotherapeutics is more attractive than Kodiak Sciences.

Arcutis Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kodiak Sciences has a beta of 2.113, suggesting its more volatile than the S&P 500 by 111.317%.

Arcutis Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kodiak Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics pays -- of its earnings as a dividend. Kodiak Sciences pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics quarterly revenues are $44.8M, which are larger than Kodiak Sciences quarterly revenues of --. Arcutis Biotherapeutics's net income of -$41.5M is higher than Kodiak Sciences's net income of -$43.9M. Notably, Arcutis Biotherapeutics's price-to-earnings ratio is -- while Kodiak Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics is 12.54x versus -- for Kodiak Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -92.81% compared to Arcutis Biotherapeutics's net margin of -219.3%. Arcutis Biotherapeutics's return on equity of -138.99% beat Spero Therapeutics's return on equity of 4.36%.

Arcutis Biotherapeutics has a consensus price target of $19.13, signalling upside risk potential of 25.25%. On the other hand Spero Therapeutics has an analysts' consensus of -- which suggests that it could grow by 400%. Given that Spero Therapeutics has higher upside potential than Arcutis Biotherapeutics, analysts believe Spero Therapeutics is more attractive than Arcutis Biotherapeutics.

Arcutis Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spero Therapeutics has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.173%.

Arcutis Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics quarterly revenues are $44.8M, which are larger than Spero Therapeutics quarterly revenues of $7.8M. Arcutis Biotherapeutics's net income of -$41.5M is lower than Spero Therapeutics's net income of -$17.1M. Notably, Arcutis Biotherapeutics's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 12.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics is 12.54x versus 0.60x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -92.81% compared to Arcutis Biotherapeutics's net margin of 37.71%. Arcutis Biotherapeutics's return on equity of -138.99% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Arcutis Biotherapeutics has a consensus price target of $19.13, signalling upside risk potential of 25.25%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.64 which suggests that it could grow by 19.78%. Given that Arcutis Biotherapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Arcutis Biotherapeutics is more attractive than Vertex Pharmaceuticals.

Arcutis Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.102%.

Arcutis Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics quarterly revenues are $44.8M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Arcutis Biotherapeutics's net income of -$41.5M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Arcutis Biotherapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics is 12.54x versus 10.09x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.